CEB 925
Latest Information Update: 05 Oct 2011
At a glance
- Originator Wyeth
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 19 Sep 2000 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)
- 09 Apr 1998 New profile
- 09 Apr 1998 Phase-I clinical trials for Hyperlipidaemia in USA (Unknown route)